

Dated: February 21, 1996.  
Paul Andrews,  
*Acting District Manager.*  
[FR Doc. 96-4868 Filed 3-1-96; 8:45 am]  
BILLING CODE 4310-DQ-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated September 29, 1995, and published in the Federal Register on October 11, 1995, (60 FR 52923), Ciba-Geigy Corporation, Pharmaceuticals Division Regulatory Compliance, 556 Morris Avenue, Summit, New Jersey 07901, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Ciba-Geigy Corporation to manufacture the listed controlled substance is consistent with the public interest at this time. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, Section 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Gene R. Haislip,  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*  
[FR Doc. 96-4946 Filed 3-1-96; 8:45 am]  
BILLING CODE 4410-09-M

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated October 19, 1995, and published in the Federal Register on October 25, 1995, (60 FR 54707), Eli Lilly Industries, Inc., Chemical Plant, Kilometer 146 7, State Road 2, Mayaguez, Puerto Rico 00680, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of dextropropoxyphene, bulk (non-dosage forms) (9273), a basic class of controlled substance listed in Schedule II.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Eli Lilly Industries, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, Section 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: February 26, 1996.  
Gene R. Haislip,  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*  
[FR Doc. 96-4947 Filed 3-1-96; 8:45 am]  
BILLING CODE 4410-09-M

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 13, 1995, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug                             | Schedule |
|----------------------------------|----------|
| 2,5-Dimethoxyamphetamine (7396)  | I        |
| Difenoxin (9168)                 | I        |
| Methylphenidate (1724)           | II       |
| Codeine (9050)                   | II       |
| Oxycodone (9143)                 | II       |
| Hydromorphone (9150)             | II       |
| Diphenoxylate (9170)             | II       |
| Hydrocodone (9193)               | II       |
| Levorphanol (9220)               | II       |
| Meperidine (9230)                | II       |
| Meperidine intermediate-A (9232) | II       |
| Meperidine intermediate-B (9233) | II       |
| Meperidine intermediate-C (9234) | II       |
| Methadone (9250)                 | II       |
| Methadone intermediate (9254)    | II       |
| Oxymorphone (9652)               | II       |
| Morphine (9300)                  | II       |
| Oxymorphone (9652)               | II       |
| Sufentanil (9740)                | II       |
| Carfentanil (9743)               | II       |
| Fentanyl (9801)                  | II       |

The firm plans to manufacture the listed controlled substances in bulk to supply final dosage form manufacturers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 3, 1996.

Dated: February 26, 1996.  
Gene R. Haislip,  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*  
[FR Doc. 96-4944 Filed 3-1-96; 8:45 am]  
BILLING CODE 4410-09-M

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 19, 1995, MD Pharmaceutical, Inc., 3501 West Garry Avenue, Santa Ana, California 92704, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug                   | Schedule |
|------------------------|----------|
| Methylphenidate (1724) | II       |
| Diphenoxylate (9170)   | II       |

The firm plans to manufacture the listed controlled substances to make finished dosage forms for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objects to the issuance of the above application.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 3, 1996.